Hemispherx Biopharma Signs Clinical Trial Agreement With Roswell Park Comprehensive Cancer Center To Study Ampligen In Combination With Checkpoint Inhibitors In Phase IIa Study On Urothelial Carcinoma, Renal Cell Carcinoma And Melanoma